US biotech firm Fractyl Health is developing Rejuva, an experimental gene therapy that may mimic GLP-1 drugs for years after ...

These drugs work by targeting GLP-1, a satiety hormone that has been sh… ...

USA: Therapy with glucagon-like peptide-1 receptor agonists (GLP-1RAs) after heart transplantation was associated with ...

GLP-1 RA use is associated with improved survival and lower hospitalization rates in patients with type 2 diabetes receiving cancer therapy.

Use of liraglutide or semaglutide therapy does not increase risk for thyroid cancer among patients with type 2 diabetes or obesity.

By Tarun Sai Lomte An expert editorial suggests that widely used diabetes and obesity drugs may help close the long-standing ...

With the advent of oral obesity treatments as an alternative to injections, interest in obesity therapy is intensifying in ...

By Vijay Kumar Malesu New trial evidence shows that without structured exercise, weight loss medications may leave physical ...

Sun Pharmaceutical Industries announced that it has received approval from the Drugs Controller General of India (DCGI) to manufacture and market a generic version of semaglutide injection.

Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist indicated for weight management as an adjunct to a reduced-calorie diet and increased physical activity.

Recently, GLP-1 (glucagon-like peptide-1) class obesity treatments such as ‘Wegovy’ and ‘Mounjaro’ have gained immense ...

Mumbai: Global pharmaceutical major Lupin Limited on Tuesday announced a licensing and supply agreement through its ...